Literature DB >> 25311365

Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTOR.

A Oguro-Ando1,2, C Rosensweig1, E Herman1, Y Nishimura1, D Werling1, B R Bill1, J M Berg1, F Gao1, G Coppola1,3, B S Abrahams1, D H Geschwind1,4.   

Abstract

Rare maternally inherited duplications at 15q11-13 are observed in ~1% of individuals with an autism spectrum disorder (ASD), making it among the most common causes of ASD. 15q11-13 comprises a complex region, and as this copy number variation encompasses many genes, it is important to explore individual genotype-phenotype relationships. Cytoplasmic FMR1-interacting protein 1 (CYFIP1) is of particular interest because of its interaction with Fragile X mental retardation protein (FMRP), its upregulation in transformed lymphoblastoid cell lines from patients with duplications at 15q11-13 and ASD and the presence of smaller overlapping deletions of CYFIP1 in patients with schizophrenia and intellectual disability. Here, we confirm that CYFIP1 is upregulated in transformed lymphoblastoid cell lines and demonstrate its upregulation in the post-mortem brain from 15q11-13 duplication patients for the first time. To investigate how increased CYFIP1 dosage might predispose to neurodevelopmental disease, we studied the consequence of its overexpression in multiple systems. We show that overexpression of CYFIP1 results in morphological abnormalities including cellular hypertrophy in SY5Y cells and differentiated mouse neuronal progenitors. We validate these results in vivo by generating a BAC transgenic mouse, which overexpresses Cyfip1 under the endogenous promotor, observing an increase in the proportion of mature dendritic spines and dendritic spine density. Gene expression profiling on embryonic day 15 suggested the dysregulation of mammalian target of rapamycin (mTOR) signaling, which was confirmed at the protein level. Importantly, similar evidence of mTOR-related dysregulation was seen in brains from 15q11-13 duplication patients with ASD. Finally, treatment of differentiated mouse neuronal progenitors with an mTOR inhibitor (rapamycin) rescued the morphological abnormalities resulting from CYFIP1 overexpression. Together, these data show that CYFIP1 overexpression results in specific cellular phenotypes and implicate modulation by mTOR signaling, further emphasizing its role as a potential convergent pathway in some forms of ASD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25311365      PMCID: PMC4409498          DOI: 10.1038/mp.2014.124

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  78 in total

Review 1.  Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond.

Authors:  Aaron W Grossman; Georgina M Aldridge; Ivan Jeanne Weiler; William T Greenough
Journal:  J Neurosci       Date:  2006-07-05       Impact factor: 6.167

2.  Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.

Authors:  Robert P Carson; Dominic L Van Nielen; Peggy A Winzenburger; Kevin C Ess
Journal:  Neurobiol Dis       Date:  2011-08-26       Impact factor: 5.996

3.  Autism genome-wide copy number variation reveals ubiquitin and neuronal genes.

Authors:  Joseph T Glessner; Kai Wang; Guiqing Cai; Olena Korvatska; Cecilia E Kim; Shawn Wood; Haitao Zhang; Annette Estes; Camille W Brune; Jonathan P Bradfield; Marcin Imielinski; Edward C Frackelton; Jennifer Reichert; Emily L Crawford; Jeffrey Munson; Patrick M A Sleiman; Rosetta Chiavacci; Kiran Annaiah; Kelly Thomas; Cuiping Hou; Wendy Glaberson; James Flory; Frederick Otieno; Maria Garris; Latha Soorya; Lambertus Klei; Joseph Piven; Kacie J Meyer; Evdokia Anagnostou; Takeshi Sakurai; Rachel M Game; Danielle S Rudd; Danielle Zurawiecki; Christopher J McDougle; Lea K Davis; Judith Miller; David J Posey; Shana Michaels; Alexander Kolevzon; Jeremy M Silverman; Raphael Bernier; Susan E Levy; Robert T Schultz; Geraldine Dawson; Thomas Owley; William M McMahon; Thomas H Wassink; John A Sweeney; John I Nurnberger; Hilary Coon; James S Sutcliffe; Nancy J Minshew; Struan F A Grant; Maja Bucan; Edwin H Cook; Joseph D Buxbaum; Bernie Devlin; Gerard D Schellenberg; Hakon Hakonarson
Journal:  Nature       Date:  2009-04-28       Impact factor: 49.962

Review 4.  Imprinting in Angelman and Prader-Willi syndromes.

Authors:  Y Jiang; T F Tsai; J Bressler; A L Beaudet
Journal:  Curr Opin Genet Dev       Date:  1998-06       Impact factor: 5.578

5.  Selective regulation of GluA subunit synthesis and AMPA receptor-mediated synaptic function and plasticity by the translation repressor 4E-BP2 in hippocampal pyramidal cells.

Authors:  Israeli Ran; Christos G Gkogkas; Cristina Vasuta; Maylis Tartas; Arkady Khoutorsky; Isabel Laplante; Armen Parsyan; Tatiana Nevarko; Nahum Sonenberg; Jean-Claude Lacaille
Journal:  J Neurosci       Date:  2013-01-30       Impact factor: 6.167

6.  Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.

Authors:  Aditi Bhattacharya; Hanoch Kaphzan; Amanda C Alvarez-Dieppa; Jaclyn P Murphy; Philippe Pierre; Eric Klann
Journal:  Neuron       Date:  2012-10-17       Impact factor: 17.173

7.  The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP.

Authors:  Ilaria Napoli; Valentina Mercaldo; Pietro Pilo Boyl; Boris Eleuteri; Francesca Zalfa; Silvia De Rubeis; Daniele Di Marino; Evita Mohr; Marzia Massimi; Mattia Falconi; Walter Witke; Mauro Costa-Mattioli; Nahum Sonenberg; Tilmann Achsel; Claudia Bagni
Journal:  Cell       Date:  2008-09-19       Impact factor: 41.582

8.  KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant.

Authors:  Christelle Golzio; Jason Willer; Michael E Talkowski; Edwin C Oh; Yu Taniguchi; Sébastien Jacquemont; Alexandre Reymond; Mei Sun; Akira Sawa; James F Gusella; Atsushi Kamiya; Jacques S Beckmann; Nicholas Katsanis
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

9.  Large recurrent microdeletions associated with schizophrenia.

Authors:  Hreinn Stefansson; Dan Rujescu; Sven Cichon; Olli P H Pietiläinen; Andres Ingason; Stacy Steinberg; Ragnheidur Fossdal; Engilbert Sigurdsson; Thordur Sigmundsson; Jacobine E Buizer-Voskamp; Thomas Hansen; Klaus D Jakobsen; Pierandrea Muglia; Clyde Francks; Paul M Matthews; Arnaldur Gylfason; Bjarni V Halldorsson; Daniel Gudbjartsson; Thorgeir E Thorgeirsson; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Aslaug Jonasdottir; Asgeir Bjornsson; Sigurborg Mattiasdottir; Thorarinn Blondal; Magnus Haraldsson; Brynja B Magnusdottir; Ina Giegling; Hans-Jürgen Möller; Annette Hartmann; Kevin V Shianna; Dongliang Ge; Anna C Need; Caroline Crombie; Gillian Fraser; Nicholas Walker; Jouko Lonnqvist; Jaana Suvisaari; Annamarie Tuulio-Henriksson; Tiina Paunio; Timi Toulopoulou; Elvira Bramon; Marta Di Forti; Robin Murray; Mirella Ruggeri; Evangelos Vassos; Sarah Tosato; Muriel Walshe; Tao Li; Catalina Vasilescu; Thomas W Mühleisen; August G Wang; Henrik Ullum; Srdjan Djurovic; Ingrid Melle; Jes Olesen; Lambertus A Kiemeney; Barbara Franke; Chiara Sabatti; Nelson B Freimer; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Ole A Andreassen; Roel A Ophoff; Alexander Georgi; Marcella Rietschel; Thomas Werge; Hannes Petursson; David B Goldstein; Markus M Nöthen; Leena Peltonen; David A Collier; David St Clair; Kari Stefansson
Journal:  Nature       Date:  2008-09-11       Impact factor: 49.962

10.  Opposite effects on facial morphology due to gene dosage sensitivity.

Authors:  Peter Hammond; Shane McKee; Michael Suttie; Judith Allanson; Jan-Maarten Cobben; Saskia M Maas; Oliver Quarrell; Ann C M Smith; Suzanne Lewis; May Tassabehji; Sanjay Sisodiya; Teresa Mattina; Raoul Hennekam
Journal:  Hum Genet       Date:  2014-06-03       Impact factor: 4.132

View more
  48 in total

1.  Altered mTORC1 signaling in multipotent stem cells from nearly 25% of patients with nonsyndromic autism spectrum disorders.

Authors:  A M Suzuki; K Griesi-Oliveira; C de Oliveira Freitas Machado; E Vadasz; E C Zachi; M R Passos-Bueno; A L Sertie
Journal:  Mol Psychiatry       Date:  2015-01-13       Impact factor: 15.992

Review 2.  Advancing the understanding of autism disease mechanisms through genetics.

Authors:  Luis de la Torre-Ubieta; Hyejung Won; Jason L Stein; Daniel H Geschwind
Journal:  Nat Med       Date:  2016-04       Impact factor: 53.440

3.  Domain-Specific Cognitive Impairments in Humans and Flies With Reduced CYFIP1 Dosage.

Authors:  Young Jae Woo; Alexandros K Kanellopoulos; Parisa Hemati; Jill Kirschen; Rebecca A Nebel; Tao Wang; Claudia Bagni; Brett S Abrahams
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

4.  Collybistin binds and inhibits mTORC1 signaling: a potential novel mechanism contributing to intellectual disability and autism.

Authors:  Camila Oliveira Freitas Machado; Karina Griesi-Oliveira; Carla Rosenberg; Fernando Kok; Stephanie Martins; Maria Rita Passos-Bueno; Andrea Laurato Sertie
Journal:  Eur J Hum Genet       Date:  2015-04-22       Impact factor: 4.246

5.  Novel West syndrome candidate genes in a Chinese cohort.

Authors:  Jing Peng; Ying Wang; Fang He; Chen Chen; Li-Wen Wu; Li-Fen Yang; Yu-Ping Ma; Wen Zhang; Zi-Qing Shi; Chao Chen; Kun Xia; Hui Guo; Fei Yin; Nan Pang
Journal:  CNS Neurosci Ther       Date:  2018-04-17       Impact factor: 5.243

Review 6.  Lessons learned from studying syndromic autism spectrum disorders.

Authors:  Yehezkel Sztainberg; Huda Y Zoghbi
Journal:  Nat Neurosci       Date:  2016-10-26       Impact factor: 24.884

7.  Cytoplasmic FMRP interacting protein 1/2 (CYFIP1/2) expression analysis in autism.

Authors:  Rezvan Noroozi; Mir Davood Omrani; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  Metab Brain Dis       Date:  2018-05-11       Impact factor: 3.584

8.  Genetic and morphological features of human iPSC-derived neurons with chromosome 15q11.2 (BP1-BP2) deletions.

Authors:  D K Das; V Tapias; L D'Aiuto; K V Chowdari; L Francis; Y Zhi; Bhattacharjee A Ghosh; U Surti; J Tischfield; M Sheldon; J C Moore; K Fish; V Nimgaonkar
Journal:  Mol Neuropsychiatry       Date:  2015-06-24

9.  Expression Analysis of CYFIP1 and CAMKK2 Genes in the Blood of Epileptic and Schizophrenic Patients.

Authors:  Arezou Sayad; Fatemeh Ranjbaran; Soudeh Ghafouri-Fard; Shahram Arsang-Jang; Mohammad Taheri
Journal:  J Mol Neurosci       Date:  2018-07-11       Impact factor: 3.444

10.  Cyfip1 Regulates Presynaptic Activity during Development.

Authors:  Kuangfu Hsiao; Hala Harony-Nicolas; Joseph D Buxbaum; Ozlem Bozdagi-Gunal; Deanna L Benson
Journal:  J Neurosci       Date:  2016-02-03       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.